AptarGroup (ATR) Closures — Selling, research & development and administrative

Screener

Other segment segments

Pharma

$68.12M—

Beauty

$52.63M—

Similar metrics at other companies

ITWSelling Administrative and Research and Development Expenses

$735M+6.1%

KALUSelling Administrative Research And Development And General Expenses

$35.7M+9.5%

IQVResearch & Development Solutions — Selling, general and administrative expenses

$248M+9.3%

VPGSensors — Selling General And Administrative Expense Excluding Research And Development

$5.49M+50.5%

VSTAsset Closure — Selling, General and Administrative Expense

$15M-11.8%

VPGMeasurement Systems — Selling General And Administrative Expense Excluding Research And Development

$5M+7.9%

Other financials

Income statement

See full

Revenue$982.9M+10.8%

Gross profit$351.9M+4.6%

Operating income$107.5M-5.2%

Net income$72.7M-7.8%

EPS (diluted)$1.12-4.3%

Balance sheet

See full

Cash & equivalents$225.0M+78.8%

Total debt$1.4B+32.7%

Total equity$2.6B+3.6%

Total assets$5.1B+12.6%

Cash flow

See full

Operating cash flow$118.7M+43.5%

CapEx$65.4M+15.0%

Free cash flow$53.3M+106%

Valuation

See full

Market cap$8.69B-4.7%

Enterprise value$9.9B-2.2%

P/E22.5×-0.8×

P/S2.3×-0.3×

Profitability

See full

Gross margin36.7%-1.6pp

Operating margin12.8%-1.2pp

Net margin10%-0.4pp

FCF margin8.4%-2.1pp

Returns & leverage

See full

Return on equity15%-0.2pp

Debt / equity0.5×+0.1×

Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept atr:SellingResearchAndDevelopmentAndAdministrativeExpenses.

The source filing: AptarGroup’s 10-Q, filed May 1, 2026.

Filed: May 1, 2026, 11:22 AM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0000896622-26-000092

Three Months Ended March 31,	2026	2025
Selling, Research & Development and Administrative:
Pharma	68,116	62,483
Beauty	52,630	46,412
Closures	24,945	23,012
Other Segment Items:
Pharma	(4,315)	(603)
Beauty	(965)	(1,891)
Closures	188	(532)

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is AptarGroup's closures — selling, research & development and administrative?: AptarGroup (ATR) reported closures — selling, research & development and administrative of $24.95M in Q1 2026.
How has AptarGroup's closures — selling, research & development and administrative changed year-over-year?: AptarGroup's closures — selling, research & development and administrative increased by 8.4% year-over-year, from $23.01M to $24.95M.
What does closures — selling, research & development and administrative mean?: This includes the operating expenses related to sales, marketing, product innovation, and general management functions within the Closures segment. It reflects the investment in future growth and the overhead required to support current operations.